The invention relates to novel substituted phenyl uracils of the formula (I) ##STR00001## in which R.sup.1 represents hydrogen, amino or in each case optionally substituted alkyl, alkenyl or alkynyl, R.sup.2 represents cyano, carboxy, carbamoyl, thiocarbamoyl or optionally substituted alkyl or alkoxycarbonyl, R.sup.3 represents hydrogen, halogen or optionally substituted alkyl, R.sup.4 represents hydrogen, nitro, cyano, alkoxy or halogen, R.sup.5 represents cyano, thiocarbamoyl, halogen or optio...

Substituted pyrazoles, methods of manufacturing them, compositions containing them, and methods of using them to treat, for example, autoimmune diseases mediated by cathepsin S are described.

Substituted pyrazoles, methods of manufacturing them, compositions containing them, and methods of using them to treat, for example, autoimmune diseases mediated by cathepsin S are described.

The present invention relates to certain compounds of the formula (I), ##STR1## which are useful in the synthesis of certain .beta.-adrenergic receptor agonists. The invention also relates to a process for synthesizing the compounds of formula (I) and to compounds of the formula (II), ##STR2## wherein R.sup.1, R.sup.2 and R.sup.4 are defined herein, which are useful in the synthesis of the compounds of formula (I). The invention also relates to a process for synthesizing a compound of formula (I...

Substituted pyrazoles, methods of manufacturing them, compositions containing them, and methods of using them to treat, for example, autoimmune diseases mediated by cathepsin S are described.

Arylpyrazine compounds are provided, including arylpyrazines that can bind with high affinity and high selectivity to CRF.sub.1 receptors, including human CRF.sub.1 receptors. The invention thus includes methods for treatment of disorders and diseases associated with CRF.sub.1 receptors, including CNS-related disorders and diseases, particularly affective disorders and diseases, and acute and chronic neurological disorders and diseases.

The invention relates to novel substituted benzoylcyclohexanediones of the general formula (I), ##STR1## in which m, n, A, R.sup.1, R.sup.2, R.sup.3, R.sup.4 and Z are each as defined in the description, and also to processes for their preparation and to their use as herbicides.

Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory se...

The invention relates to novel substituted benzoylcyclohexenones of the formula (I), ##STR1## in which n, A, R.sup.1, R.sup.2, R.sup.3, R.sup.4, Y and Z are each as defined in the description, and also to processes for their preparation and to their use as herbicides.

Substituted pyrazoles, methods of manufacturing them, compositions containing them, and methods of using them to treat, for example, autoimmune diseases mediated by cathepsin S are described.